Although the gene defect responsible for Huntington's disease (HD) has recently been discovered, the means by which it leads to neuronal death remains unknown. We hypothesize that a primary or secondary consequence of the gene defect may be impairment of oxidative phosphorylation. This may then result in both oxidative damage as well as neuronal degeneration by a slow excitotoxic mechanism. We propose to examine this hypothesis using neurochemical studies in both postmortem brain tissue as well as plasma and urine of HD patients. Our first specific aim will be to determine whether there is an abnormality in any of the electron transport chain complexes and ATP synthase in HD postmortem brain tissue as compared with age-matched controls. We will determine whether changes are confined to one enzyme complex and the regional distribution of any changes. If there is defect in oxidative phosphorylation it may lead to increased oxidative damage. Our second specific aim will be to determine if there is evidence of oxidative damage to lipids, proteins or DNA in HD postmortem brain tissue. We will measure 8-hydroxy-2-deoxyguanosine as a marker of oxidative damage to nuclear and mitochondrial DNA, protein carbonyls as a marker of oxidative damage to proteins and malondialdehyde as a marker of oxidative damage to lipids. Our third specific aim is to determine whether there is evidence of impaired oxidative phosphorylation as evidenced by an increase in lactate/pyruvate rations following glucose loading in HD patients. We will also examine whether there is increased formation of 2,3 and 2,5 dihydroxybenzoic acid following salicylate loading, which would be consistent with increased hydroxyl radical generation. Both urine and plasma measurements of 8-hydroxy-2-deoxyguanosine, protein carbonyl groups and other neurochemical markers including hypoxanthine and 3-nitrotyrosine will be determined. If abnormalities are found studies will be undertaken to correlate them with numbers of CAG repeats in both symptomatic and at risk HD patients. Lastly we will determine whether either free radicals or nitric oxide play a role in neuronal degeneration following administration of either malonate or 3-nitropropionic acid. These compounds are succinate dehydrogenase inhibitors which produce lesions which closely resemble HD. If these lesions can be attenuated it would suggest that similar strategies might be useful in HD. These studies will therefore provide direct evidence as to whether there is impairment of oxidative phosphorylaiton and increased oxidative damage in both central and peripheral tissues of HD patients. They also have the potential of leading to novel therapeutic approaches to attempting to slow the degenerative process.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS016367-17
Application #
5215117
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
1996
Total Cost
Indirect Cost
Lee, Jong-Min; Chao, Michael J; Harold, Denise et al. (2017) A modifier of Huntington's disease onset at the MLH1 locus. Hum Mol Genet 26:3859-3867
HD iPSC Consortium (2017) Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci 20:648-660
Chao, Michael J; Gillis, Tammy; Atwal, Ranjit S et al. (2017) Haplotype-based stratification of Huntington's disease. Eur J Hum Genet 25:1202-1209
Shin, Aram; Shin, Baehyun; Shin, Jun Wan et al. (2017) Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels. Hum Mol Genet 26:1258-1267
Keum, Jae Whan; Shin, Aram; Gillis, Tammy et al. (2016) The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease. Am J Hum Genet 98:287-98
Ramos, Eliana Marisa; Gillis, Tammy; Mysore, Jayalakshmi S et al. (2015) Prevalence of Huntington's disease gene CAG trinucleotide repeat alleles in patients with bipolar disorder. Bipolar Disord 17:403-8
Correia, Kevin; Harold, Denise; Kim, Kyung-Hee et al. (2015) The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. J Huntingtons Dis 4:279-84
Lee, Jong-Min; Kim, Kyung-Hee; Shin, Aram et al. (2015) Sequence-Level Analysis of the Major European Huntington Disease Haplotype. Am J Hum Genet 97:435-44
Ramos, Eliana Marisa; Gillis, Tammy; Mysore, Jayalakshmi S et al. (2015) Haplotype analysis of the 4p16.3 region in Portuguese families with Huntington's disease. Am J Med Genet B Neuropsychiatr Genet 168B:135-43
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium (2015) Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell 162:516-26

Showing the most recent 10 out of 42 publications